Browse All

Current Filters

CLEAR FILTER x

TITLE

Author Institution:

ORATORIO-HAND: Results of the Primary Analysis of Ocrelizumab vs Placebo in Primary Progressive Multiple Sclerosis, Including Older Patients and Those With More Advanced Disease

Author:Giovannoni, Gavin   Airas, Laura   Bove, Riley   Cutter, Gary   Hobart, Jeremy   Kuhle, Jens   Montalban, Xavier   Tur, Carmen   Wolinsky, Jerry   Schneble, Hans-Martin   Baldinotti, Anna   Bonati, Ulrike   Giacobino, Caroline   Wang, Qing   Yang, Ke   Oh, Jiwon   

Session Name:S40: Multiple Sclerosis: Clinical Trials/Science and Real-world Evidence  

Topic:Multiple Sclerosis  

Program Number:S40.001  

Author Institution:Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, UK and Blizard Institute, Queen Mary University, London, UK, London, United Kingdom  University of Turku, Turku, Finland, Turku, Finland  UCSF Weill Institute for Neuroscience, Department of Neurology, University of California San Francisco, San Francisco, CA, USA, CA  The University of Alabama at Birmingham, School of Public Health, Birmingham, AL, USA, Birmingham, AL  Peninsula Medical School, Plymouth University, UK, Plymouth, United Kingdom  MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland, Switzerland  Centre d'Esclerosi Múltiple de Catalunya, Vall d'Hebron University Hospital, Barcelona, Spain, Barcelona, Spain  Queen Square MS Centre, Department of Neuroinflammation, Institute of Neurology, Faculty of Brain Sciences, University College London (UCL), London, UK/Neurology-Neuroimmunology Department, Multiple Sclerosis Centre of Catalonia (CEMCAT), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain, Un  Department of Neurology, University of Texas Health Science Center, Houston, TX, USA, TX  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Switzerland  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  Division of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada, ON, Canada  

Efficacy and Safety of Zilganersen, an Investigational RNA-targeted Antisense Therapy, in People Living with Alexander Disease: Results from a Pivotal Study

Author:Waldman, Amy   Lynch, David   Tonduti, Davide   Van Der Knaap, Marjo   Bernard, Geneviève   Eichler, Florian   Sampson, Jacinda   Zerem, Ayelet   Chataway, Jeremy   Cunningham, Chloe   Bertini, Enrico   Hacohen, Yael   Saito, Takashi   Keller, Stephanie   Vaia, Ylenia   Kim, Nee Na   Nagy, Amanda   Van Haren, Keith   Van den Berg, Elske   Chen, Chen   Ruiz, Norma   Collins, Abigail   Smith, Anne   

Session Name:PL5: Clinical Trials Plenary Session  

Topic:Child Neurology and Developmental Neurology  

Program Number:PL5.003  

Author Institution:Division of Neurology, Children’s Hospital of Philadelphia, and Departments of Neurology and Pediatrics, Perelman School of Medicine at the University of Pennsylvania, PA  Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London  National Institute for Health Research, University College London Hospitals, Biomedical Research Centre  Inherited White Matter Disorders Highly Specialised Service, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, United Kingdom  Unit of Pediatric Neurology, COALA (Center for Diagnosis and Treatment of Leukodystrophies), V. Buzzi Children's Hospital, University of Milan, MILANO, Italy  Department of Child Neurology, Amsterdam Leukodystrophy Center, Emma Children's Hospital, Amsterdam, Netherlands  Department of Neurology and Neurosurgery, Pediatrics and Human Genetics, McGill University, QC, Canada  Department of Neurology, Massachusetts General Hospital, Harvard Medical School, and the Center for Genomic Medicine, Massachusetts General Hospital, MA  Department of Neurology and Neurological Sciences, Stanford Neuroscience Health Center, Palo Alto, CA  Dana-Dwek Children’s Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel  Murdoch Children’s Research Institute, Parkville, Australia  Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy  Department of Pediatric Neurology, Great Ormond Street Hospital for Children, United Kingdom  Department of Child Neurology , National Center of Neurology and Psychiatry, Kodaira, Japan  Department of Pediatrics, Division of Pediatric Neurology, Emory University School of Medicine, GA  Unit of Pediatric Neurology, COALA (Center for Diagnosis and Treatment of Leukodystrophies), V. Buzzi Children's Hospital, University of Milan, Milan, Italy  Department of Neurology, Great Ormond Street Hospital for Children, United Kingdom  Department of Neurology, Massachusetts General Hospital, Harvard Medical School, and the Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA  Department of Child Neurology, Amsterdam Leukodystrophy Center, Emma Children's Hospital, Netherlands  Ionis, CA  Ionis, Carlsbad, CA  

Association Between Disease-modifying Therapies for Multiple Sclerosis and Cancer Reporting: A Disproportionality Analysis Using the U.S. Food and Drug Administration Adverse Event Reporting System Database